Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GCN2 modulator HC-7366-K

An immediate release (IR) capsule formulation of the potassium salt monohydrate form of HC-7366, a modulator of the serine/threonine protein kinase general control nonderepressible 2 (GCN2), with potential antineoplastic and immunomodulating activities. Upon oral administration, the base moiety HC-7366 of the GCN2 modulator HC-7366-K targets and binds to GCN2. This prevents GCN2 activity and GCN2-mediated signaling. This may induce apoptosis in tumor cells that rely on GCN2 signaling for survival. In addition, as GCN2 signaling reduces anti-tumor immunity, preventing GCN2 signaling may enhance anti-tumor immune responses. GCN2 plays a key role in the activation of the integrated stress response (ISR) pathway in response to amino acid deprivation and in hypoxic tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:general control nonderepressible 2 modulator HC-7366-K
Code name:HC 7366-K
HC-7366-K
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search